Drugs & Targets FDA approves Aucatzyl for adults with r/r B-cell precursor ALL November 15, 2024Vol.50 No.43
Drugs & Targets Tempus, Flatiron collaborate to expand point of care through OncoEMR integration November 15, 2024Vol.50 No.43
Drugs & Targets Humana and Evolent expand partnership to enhance oncology care November 15, 2024Vol.50 No.43
Drugs & Targets Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product November 15, 2024Vol.50 No.43
Editorial What will Trump’s return to the White House mean for oncology?“Our work just got a lot more difficult.” November 08, 2024Vol.50 No.42By Paul Goldberg
At an uncertain time for cancer research and public health, Wayne Frederick steps in as interim CEO at ACS November 08, 2024Vol.50 No.42By Paul Goldberg
Trials & Tribulations A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment November 08, 2024Vol.50 No.42By Otis W. Brawley
Conversation with The Cancer Letter 2024 Harry Hynes Award winner Judith Hopkins on being a doctor in 1977, mentorship, and the benefits of community practice November 08, 2024Vol.50 No.42By Jacquelyn Cobb
Arteaga, Bhardwaj, Coussens, Jagsi, Schrag named members of the National Academy of Medicine November 08, 2024Vol.50 No.42By Jacquelyn Cobb
In Brief Jennifer Bickel named vice president and chief wellness officer at MD Anderson November 08, 2024Vol.50 No.42
